. Correction to: The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol Dial Transplant 2023 Nov 30:gfad252. doi: 10.1093.
PMID: 38033315